AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cyclo Therapeutics Inc. (CYTH)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.95

0.00 (0.00%)

At close: Feb 20, 2025, 3:58 PM

0.91

-4.40%

After-hours: Feb 20, 2025, 06:09 PM EST

undefined% (undefined)

Bid	0.91
Market Cap	27.24M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.9
PE Ratio (ttm)	-1.06
Forward PE	n/a
Analyst	Hold

Ask	0.97
Volume	92,692
Avg. Volume (20D)	1,550,159
Open	0.92
Previous Close	0.95
Day's Range	0.88 - 0.96
52-Week Range	0.55 - 1.79
Beta	undefined

About CYTH

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, n...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 3, 2000

Employees 8

Stock Exchange NASDAQ

Ticker Symbol CYTH

Website https://www.cyclotherapeutics.com

Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for CYTH stock is "Hold." The 12-month stock price forecast is $0.95, which is a decrease of -0.20% from the latest price.

Buy 33.33%

Hold 66.67%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Cyclo Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+54.55%

Cyclo Therapeutics shares are trading higher after... Unlock content with Pro Subscription

6 months ago

-26.98%

Cyclo Therapeutics shares are trading lower after the company announced it agreed to merge with Rafael Holdings.

News

20 hours ago · businesswire.com

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeu...

1 week ago · businesswire.com

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medici...